FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303962015> ?p ?o ?g. }

• W4303962015 endingPage "1216" @default.
• W4303962015 startingPage "1216" @default.
• W4303962015 abstract "There is a need to improve current cancer treatment regimens to reduce systemic toxicity, to positively impact the quality-of-life post-treatment. We hypothesized the negation of off-target toxicity of anthracyclines (e.g., Doxorubicin) by delivering Doxorubicin on magneto-electric silica nanoparticles (Dox-MagSiNs) to cancer cells. Dox-MagSiNs were completely biocompatible with all cell types and are therapeutically inert till the release of Doxorubicin from the MagSiNs at the cancer cells location. The MagSiNs themselves are comprised of biocompatible components with a magnetostrictive cobalt ferrite core (4−6 nm) surrounded by a piezoelectric fused silica shell of 1.5 nm to 2 nm thickness. The MagSiNs possess T2-MRI contrast properties on par with RESOVIST™ due to their cobalt ferrite core. Additionally, the silica shell surrounding the core was volume loaded with green or red fluorophores to fluorescently track the MagSiNs in vitro. This makes the MagSiNs a suitable candidate for trackable, drug nanocarriers. We used metastatic triple-negative breast cancer cells (MDAMB231), ovarian cancer cells (A2780), and prostate cancer cells (PC3) as our model cancer cell lines. Human umbilical vein endothelial cells (HUVEC) were used as control cell lines to represent blood-vessel cells that suffer from the systemic toxicity of Doxorubicin. In the presence of an external magnetic field that is 300× times lower than an MRI field, we successfully nanoporated the cancer cells, then triggered the release of 500 nM of doxorubicin from Dox-MagSiNs to successfully kill >50% PC3, >50% A2780 cells, and killed 125% more MDAMB231 cells than free Dox.HCl. In control HUVECs, the Dox-MagSiNs did not nanoporate into the HUVECS and did not exhibited any cytotoxicity at all when there was no triggered release of Dox.HCl. Currently, the major advantages of our approach are, (i) the MagSiNs are biocompatible in vitro and in vivo; (ii) the label-free nanoporation of Dox-MagSiNs into cancer cells and not the model blood vessel cell line; (iii) the complete cancellation of the cytotoxicity of Doxorubicin in the Dox-MagSiNs form; (iv) the clinical impact of such a nanocarrier will be that it will be possible to increase the current upper limit for cumulative-dosages of anthracyclines through multiple dosing, which in turn will improve the anti-cancer efficacy of anthracyclines." @default.
• W4303962015 created "2022-10-10" @default.
• W4303962015 creator A5002208567 @default.
• W4303962015 creator A5006603399 @default.
• W4303962015 creator A5010371718 @default.
• W4303962015 creator A5021788530 @default.
• W4303962015 creator A5022661110 @default.
• W4303962015 creator A5034090671 @default.
• W4303962015 creator A5042495577 @default.
• W4303962015 creator A5049239103 @default.
• W4303962015 creator A5055411404 @default.
• W4303962015 creator A5061873340 @default.
• W4303962015 creator A5071674649 @default.
• W4303962015 date "2022-09-30" @default.
• W4303962015 modified "2023-09-30" @default.
• W4303962015 title "Biocompatible, Multi-Mode, Fluorescent, T2 MRI Contrast Magnetoelectric-Silica Nanoparticles (MagSiNs), for On-Demand Doxorubicin Delivery to Metastatic Cancer Cells" @default.
• W4303962015 cites W1504408927 @default.
• W4303962015 cites W1602031286 @default.
• W4303962015 cites W1867757591 @default.
• W4303962015 cites W1919553612 @default.
• W4303962015 cites W1969018013 @default.
• W4303962015 cites W1973380761 @default.
• W4303962015 cites W1974302367 @default.
• W4303962015 cites W1978870288 @default.
• W4303962015 cites W1981736757 @default.
• W4303962015 cites W1995698553 @default.
• W4303962015 cites W2026227550 @default.
• W4303962015 cites W2030003406 @default.
• W4303962015 cites W2031061254 @default.
• W4303962015 cites W2039038263 @default.
• W4303962015 cites W2040540972 @default.
• W4303962015 cites W2041360135 @default.
• W4303962015 cites W2049737823 @default.
• W4303962015 cites W2051357882 @default.
• W4303962015 cites W2051583499 @default.
• W4303962015 cites W2053890812 @default.
• W4303962015 cites W2054745605 @default.
• W4303962015 cites W2057963838 @default.
• W4303962015 cites W2067821900 @default.
• W4303962015 cites W2080437521 @default.
• W4303962015 cites W2085212536 @default.
• W4303962015 cites W2102951227 @default.
• W4303962015 cites W2107212157 @default.
• W4303962015 cites W2122071242 @default.
• W4303962015 cites W2124366608 @default.
• W4303962015 cites W2129676318 @default.
• W4303962015 cites W2133528707 @default.
• W4303962015 cites W2140988645 @default.
• W4303962015 cites W2143628582 @default.
• W4303962015 cites W2164343988 @default.
• W4303962015 cites W2201192914 @default.
• W4303962015 cites W2283047478 @default.
• W4303962015 cites W2290839041 @default.
• W4303962015 cites W2409278088 @default.
• W4303962015 cites W2413754014 @default.
• W4303962015 cites W2505521434 @default.
• W4303962015 cites W2585859558 @default.
• W4303962015 cites W2610791577 @default.
• W4303962015 cites W2720066394 @default.
• W4303962015 cites W2724894064 @default.
• W4303962015 cites W2734635634 @default.
• W4303962015 cites W2770707426 @default.
• W4303962015 cites W2781699305 @default.
• W4303962015 cites W2793561140 @default.
• W4303962015 cites W2793791746 @default.
• W4303962015 cites W2811445828 @default.
• W4303962015 cites W2886997484 @default.
• W4303962015 cites W2887117787 @default.
• W4303962015 cites W2913044102 @default.
• W4303962015 cites W2920601105 @default.
• W4303962015 cites W2943530387 @default.
• W4303962015 cites W2947064027 @default.
• W4303962015 cites W2951245670 @default.
• W4303962015 cites W2987120930 @default.
• W4303962015 cites W3005102572 @default.
• W4303962015 cites W3010944099 @default.
• W4303962015 cites W3021982504 @default.
• W4303962015 cites W3103214745 @default.
• W4303962015 cites W3125385190 @default.
• W4303962015 cites W4234281329 @default.
• W4303962015 doi "https://doi.org/10.3390/ph15101216" @default.
• W4303962015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36297329" @default.
• W4303962015 hasPublicationYear "2022" @default.
• W4303962015 type Work @default.
• W4303962015 citedByCount "2" @default.
• W4303962015 countsByYear W43039620152022 @default.
• W4303962015 countsByYear W43039620152023 @default.
• W4303962015 crossrefType "journal-article" @default.
• W4303962015 hasAuthorship W4303962015A5002208567 @default.
• W4303962015 hasAuthorship W4303962015A5006603399 @default.
• W4303962015 hasAuthorship W4303962015A5010371718 @default.
• W4303962015 hasAuthorship W4303962015A5021788530 @default.
• W4303962015 hasAuthorship W4303962015A5022661110 @default.
• W4303962015 hasAuthorship W4303962015A5034090671 @default.
• W4303962015 hasAuthorship W4303962015A5042495577 @default.
• W4303962015 hasAuthorship W4303962015A5049239103 @default.
• W4303962015 hasAuthorship W4303962015A5055411404 @default.
• W4303962015 hasAuthorship W4303962015A5061873340 @default.

• next